Vertex Paying 102% Premium: Is the Crinetics Deal Worth It?
Vertex is pursuing Crinetics with a substantial all-cash offer. This deep dive breaks down what the $10 billion bid m...
When To Choose Index Fund Over Target Date Retirement
Learn the scenarios where index funds outperform target date funds, with emphasis on fees, control, and asset allocation flexibility.
26,348 articles
Karoline Leavitt’s $1,375 Hermès Blanket: The Costs of Motherhood
A luxury baby blanket priced at $1,375 has become a symbol of how motherhood in America comes with outsize costs. Thi...
ServisFirst Gets Axed Champlain: Major Drawdown Signal
A big hedge fund dumped its entire ServisFirst stake, triggering questions about risk and valuation in regional banks...
Ripple (XRP) News: SBI Group Builds Japan's First XRP ETF
SBI Holdings plans two ETFs, including Japan's first XRP product, aiming to attract billions in assets as Japan updat...
Investors Rushing to TIPS ETFs Face Inflation Risk
Investors rushing tips etfs have flooded inflation hedges amid stubborn price pressures, yet experts warn the protect...
FedEx Following FedEx Freight: Is Now a Buy Opportunity?
FedEx recently spun off its FedEx Freight unit, creating two focused companies. This article explains what that move ...
Kyverna Therapeutics vs Vertex Pharmaceuticals: 2026 Buy Guide
In 2026, investors face a critical choice between a clinical-stage biotech and a cash-flow powerhouse. This guide com...
Ehang Holdings Stock Crashed: Key Risks and Takeaways
A dramatic earnings miss sent EHang stocks lower, highlighting the challenges facing early-stage eVTOL developers. Th...
Strategy's Saylor Acknowledges 'Volatility' Test for STRC
Bitcoin weakness pushes STRC to new lows as strategy's Saylor acknowledges 'volatility' as a real market test. This g...
Strategy Sheds $216 Million in Bitcoin Sale, Markets React
Strategy disclosed a record Bitcoin liquidation of $216 million over the past week, signaling a dramatic shift toward...
Is Viking Therapeutics Stock Really Heading Higher
Investors often chase big biotech gains, but Viking Therapeutics stock really hinges on milestones and cash runway. T...
Bezos’ Blue Origin Raising Outside Capital to Compete
Blue Origin plans a $10 billion round at a $130 billion valuation, backed by Jeff Bezos and institutional investors. ...
Popular Topics
Fable
Smart Money Moves For Everyday Life
Investment Strategies In Energy Sector
Best Index Funds For Retirement
Investment Strategies
Untitled D6eff7ea
Crypto For Beginners
Best Dividend Etfs
Index
Innovative Skincare Clinical
Dutch Salary
Blue Owl
Budget
Ai Healthcare News
Penalty Vs No Penalty Depending On Lock Status